DreaMS - Digital Biomarkers for Multiple Sclerosis

Multiple Sclerosis Clinical Trial

— DreaMS  

Official title:

DreaMS - Development of Digital Biomarkers in Multiple Sclerosis - Feasibility Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04413032
• Other study ID #: DreaMS_2020F
• Status: Completed
• Phase: N/A
• Start date: October 5, 2020
• Est. completion date: February 26, 2021

Study information

• Verified date: March 2021
• Source: Research Center for Clinical Neuroimmunology and Neuroscience Basel
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Investigators have developed the dreaMS App, a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). Through the use of app-based tests, surveys and sensor data, the Investigators aim to identify novel types of clinical data that can be used as digital biomarkers with complementary clinical value as compared to the traditional diagnostic methods and techniques. In this feasibility study a number of digital biomarkers will be applied to test their technical reproducibility/stability and meaningfulness to patients.

Description:

Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) causing focal lesions of demyelination and diffuse neurodegeneration in the grey and white matter of the brain and spinal cord, leading to physical and cognitive disability. Currently there is a limited number of relevant biomarkers available in patients with MS, such as clinical, imaging or biological measures. Patient history and neurologic examination in combination with magnetic resonance imaging (MRI), evoked potentials and analysis of serum and cerebrospinal fluid (CSF) are the gold standard of diagnosis and mainly patient history, neurologic examination and MRI are used for patient monitoring. However, their prognostic value on a patient level is still very limited. Therefore, the scientific community and patients are in need for new and more reliable biomarkers, especially biomarkers of disease progression in order to adapt therapeutic approaches on an individual level. Digital biomarkers have the potential to fill this gap allowing for quasi-continuous measures that might be more informative than episodically collected conventional data concerning the impact of the disease on activities of daily living. The Investigators have developed the dreaMS App, a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). Through the use of app-based tests, surveys and sensor data, the Investigators aim to identify novel types of clinical data that can be used as digital biomarkers with complementary clinical value as compared to the traditional diagnostic methods and techniques. In this feasibility study a number of digital biomarkers will be applied to test their technical reproducibility/stability and meaningfulness to patients and to select the most informative for the planned validation study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: February 26, 2021
• Est. primary completion date: February 26, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Patients with MS

Inclusion Criteria:

• Age 18-70
• Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (CIS, RRMS, SPMS, PPMS)
• EDSS = 6.5
• In possession of a smart phone

Exclusion Criteria:

• Age <18 and > 70
• EDSS > 6.5
• Other clinically significant concomitant disease states (e.g., renal failure, severe hepatic dysfunction, severe/unstable cardiovascular disease, progressive cancer, etc.)
• Known or suspected non-compliance, drug or alcohol abuse
• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
• Women who are pregnant or breast feeding
• Not in possession of a smart phone Healthy Volunteers

Inclusion Criteria:

• Age 18-70
• In possession of a smart phone

Exclusion Criteria:

• Age <18 and > 70
• Diagnosis of MS
• Clinically significant concomitant disease states (e.g., renal failure, severe hepatic dysfunction, severe/unstable cardiovascular disease, progressive cancer, etc.)
• Known or suspected non-compliance, drug or alcohol abuse
• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
• Women who are pregnant or breast feeding
• Not in possession of a smart phone

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Device:
• DreaMS
The dreaMS App is a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). We analyze app-based tests, surveys and sensor data.

Locations

Country	Name	City	State
Switzerland	RC2NB	Basel

Sponsors (1)

Lead Sponsor	Collaborator
Research Center for Clinical Neuroimmunology and Neuroscience Basel

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Test Reliability of digital biomarkers measured by Intra Class Correlation	Number of digital biomarkers tested with an Intra Class Correlation of at least 0.6 if repeated 10 times	6 weeks
Primary	Test Reliability of digital biomarkers measured by Coefficient of variation	Number of digital biomarkers tested with a coefficient of Variation of less than 20% if repeated 10 times	6 weeks
Primary	Determination of user acceptance of each digital biomarker with regards to acceptance based on a questionnaire using a likert scale	Number of digital biomarkers tested with a good acceptance reflected by a mean response of more than 3 on a likert scale.	6 weeks